SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-SB
Amendment No. 4
GENERAL FORM FOR REGISTRATION OF SECURITIES OF SMALL BUSINESS ISSUERS
Under Section 12(b) or (g) of the
Securities Exchange Act of 1934
MILLENIA HOPE, INC.
-------------------------------------------------------------
(Name of Small Business Issuer in its charter)
Delaware 98-0213828
--------------------------------------------------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
4055 St. Catherine St., Suite 142, Montreal, Quebec H3Z 3J8
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(514) 846-5757
(Issuer's Telephone Number)
(514) 935-9758
(Issuer's Fax Number)
Securities to be registered under Section 12(b) of the Act:
Title of each class Name of each exchange on which
to be so registered each class is to be registered
--------------------------------- ----------------------------------
--------------------------------- ----------------------------------
Securities to be registered under Section 12(g) of the Act:
Common Stock
-------------------------------------------
(Title of Class)
<PAGE>
PART I.
Item 1. Description of Business.
(a) Business Development
Millenia Hope Inc. ("Millenia", or the "Company"), a Delaware corporation, was
organized on December 24, 1997. The Company has not been involved with any
bankruptcy, receivership or similar proceedings. The Company has not had any
material reclassification, merger, consolidation, or purchase or sale of a
significant amount of assets not in the ordinary course of business.
(b) Business of Issuer
MILLENIA was formed to further develop and distribute an anti-malarial drug
formerly known as "ASPIDOS" now called MALAREX(R) (the "Product"). As disclosed
later, the Company has also acquired the rights to another anti-material agent,
strychnos mytroides, although we are not currently pursuing the project.
Millenia's goal as a biopharmaceutical corporation is to both purchase and
develop patented drugs dealing with infectious diseases specifically, but not
exclusively, anti-malarial agents. To date, the Company has had no sales.
Further, internally generated funds are not sufficient to fund the operation of
the Company for the upcoming fiscal year. However, the officers and certain
shareholders have committed to fund the operations of the Company for the next
fiscal year. (See note 6 of the financial statements)
MALARIA, THE DISEASE
Malaria is predominant in four regions of the world:
Africa
India
South East Asia
Central and South America
Malaria parasites have been with us since the dawn of time. The current belief
is that they probably originated in Africa (along with mankind) and fossils of
mosquitoes up to 30 million years old show that the vector for malaria was
present well before the earliest recorded history.
Malaria is one of the most debilitating diseases in the developing world today.
Once thought to be virtually eradicated, malaria has resurfaced to affect over
500 million people annually. And that is only the reported cases. It is
suspected that the reported cases may represent less than one third of actual
existing cases. It is now known that mosquitoes have not only been able to
develop an immunity to the chemical insecticides used to control breeding but,
they have also developed resistance to many of the anti-malarial drugs on the
market today.
Malaria is a disease that is caused by a parasite. This parasite spends most of
its life in the red blood cells of humans. Female mosquitoes are the primary
transmittal agent for these parasites. The parasites are ingested by the female
mosquito when feeding on an infected person's blood and then spread when biting
another person. Once inside the mosquito, the parasites migrate to the salivary
glands where they are free to be transmitted with the next bite.
2
<PAGE>
Four species of malaria parasites cause disease in humans:
Plasmodium vivax
P. Malariae
P. Falciparum
P. Ovale.
The World Health Organization estimates that some 500 million people each year
are affected by malaria. The effect that malaria has on the world is truly
devastating, particularly on women. Malaria accounts for almost 3 million
deaths, a large portion of which are children. Children are dying from malaria
at the rate of 20,000 a week. Malaria is a major cause of death in first-time
mothers.
P. Falciparum is the most common and causes the majority of deaths, accounting
for approximately 90% of African and about 50% of India, South East Asia and
Latin America malaria cases. P. Falciparum is the form of malaria that Millenia
Hope is working to combat, accounting for approximately 55-60% or 275-300
million of the known cases of malaria and approximately 850,000 - 1,500,000
deaths.
Estimated lost work time for people affected with malaria is over US$ 2 billion
annually and if the trend is not reversed will soon be more than US$ 3 billion.
A single bout of malaria is estimated to cost a sum equivalent to 10-20 working
days in India or Africa.
CURRENTLY AVAILABLE TREATMENTS
In the pursuit of the eradication of malaria, scientists and researchers have
developed many different drugs to battle the parasite. As the parasite develops
a resistance to one drug, researchers must continue to look for other
combinations that will be effective in controlling the disease.
Quinine, a natural product from the bark of the cinchona tree, was one of the
first treatments for malaria and appeared in the 17th century. It is still
effective but can be toxic. Quinine remained the drug of choice for treatment
and prevention until 1942 when it was replaced by chloroquine. With widespread
chloroquine resistance, quinine together with artemether have once again become
an important treatment for malaria.
Chloroquine (Aralen), was first used in the 1940's and is a weekly treatment.
Today it is manufactured by all the major pharmaceutical companies. The first
cases of resistance were found in South America and South East Asia in the early
60's and it is now practically ineffective almost everywhere. However it is
still the most widely used anti-malarial treatment in Africa as it is the
cheapest drug available.
Sulfadoxone / pyrimethamine (Fansidar), was developed in the 1960's. The
treatment consists of three doses taken together in one day. Today, this drug is
manufactured by a number of pharmaceutical companies; the Fansidar trademark
belongs to Hoffman LaRoche. Despite widespread resistance in South East Asia and
parts of South America, it is starting to become the first line of treatment in
some African countries where chloroquine resistance is even more widespread.
3
<PAGE>
Mefloquine (Lariam), was developed by the U.S. army in the early 1980's and
commercialized by Hoffman LaRoche. Resistance has been observed since the early
1980's, particularly in the South East Asian countries.
Halofantrine, was also developed by the U.S. army and marketed by SmithKline
Beecham. In the 1990's, cross-resistance with mefloquine and side effects
(sometimes severe) have been observed.
Artemisinins, (derived from an ancient Chinese herbal remedy) comprise a family
of products. The two compounds most widely used, mainly in South East Asia, are
artemether and artesunate, They are not widely used in the developed world in
part due to toxicity fears. Due to the high rate of treatment failures,
artemisinins are now also being combined with mefloquine.
In addition to the above, there have been other drugs tested and used over the
years in the fight against malaria. Many were the forerunners of one of more of
the above. Currently many drugs based on new compounds are being tested along
with possible vaccines. The aforementioned information was reported in the
Malaria Foundation Fact Pack, May 14, 1998, Section 5.B. The Fact Pack can be
found at www.malaria.org.
An analysis of the current problems being experienced with the available drugs
as listed by the Malaria Foundation Fact Pack and summarized above leads to the
obvious conclusion that all of the above families of anti-malarial agents have
the same problem in common: the resistance developed by malaria to a greater or
lesser degree to each of the above mentioned drugs.
There is insufficient research into novel drug targets. Current new options are
based on the same three families of compounds (the quinolines, antifolates, and
artemesinin derivatives) all of which have records of resistance and or
ineffectiveness.
PRODUCT HISTORY
MALAREX
Although Millenia is a relatively new company, the existence of the natural
components of Malarex are not. Known by the Brazilian natives as "Taheebo", the
Pau Pereira is a tropical rain forest tree that exists in over 100 different
species. These trees, having healing properties, were used by indigenous
medicine men in Brazil.
Since it is a tree that has evolved in tropical rain forests, the Pau Periera
does not rot when stored at ambient temperatures. Pau Periera was used for
centuries for an assortment of applications. The tree's bark was invariably the
potion used by the natives in their therapeutic practices. It was administered
by infusion, was chewed and was even applied in poultices.
Modern scientific testing of the plant's useful properties was commenced in 1877
when a French researcher, Bochefontaine, first extracted a yellowish amorphous
alkaloid from the bark of a tree. He determined that the bark of the tree was
rich in alkaloids that have anti-viral properties. No specific research was done
on this extract to establish its anti-malarial properties until the last decade
and half.
Studies carried out in 1987 by research teams of the American Academy of
Naturopathic Medicine operating in Mexico determined that the natural Pau
Periera extract, when administered in appropriate form and dosage, is capable of
functioning as an effective immune-modulator. Once its
4
<PAGE>
efficacy became known, the teams systematically subjected the substance to
generic biochemical studies over the next several years. In order to evolve a
standardized and genetically useful plant-based remedy a carefully refined
extract had to be formulated through the stages of development. Each of them was
designed to preserve undiminished the bioavailability of its genetic components.
The final refined process using the species of tropical rainforest tree called
Peschiera Fuelsiaefolia, found in Brazil and Madagascar, was eventually
accomplished by the research team of Silvia Rossi and Guiseppe Motta operating
in Europe in 1997. Thereafter, Millenia bought all rights to MALAREX from the
co-owners of the patent applications, Mr. Rossi and Mr. Motta on January 7, 1998
(see Patents and Other Rights, pg.7). Subsequent to this sale, Mr. Motta joined
the company as its VP of Research, as a non-salaried employee who has a verbal
agreement with Millenia allowing it first right of refusal on his research
findings.
MALAREX exhibited positive results when administered to malaria patients.
Extracted from natural sources, MALAREX is not a synthetically derived drug.
MALAREX has had successful tests in the treatment and prevention of malaria and
is continuing with further ongoing tests to allow it to receive final approval
for consumer usage.
Based on our testing of MALAREX we have found that it is a product that needs no
other catalysts or chemicals in any manufacturing stages whether in capsule form
or as an injectable solution.
Throughout in-vitro (cultured cell-tests) and in-vivo (live trials) tests (see
Test Results), no undesirable side effects were detected. When treated with
MALAREX there was no need to take post treatment vitamins or other additives for
restructuring the immune system. Moreover, because of its immune-modulatory
properties (see test results - Journal of Natural Products vol. 57 November
1994), the extract is non-allergenic and non habit forming. MALAREX is still
undergoing clinical trials and the company is still waiting for the approval of
the respective country's health authorities to begin selling the product.
MALAREX (Voacamine) is produced in two forms, capsules and injectables. Because
there is a high number of malaria cases in infants, capsules are sometimes not a
viable alternative. Generally, the capsules are recommended from the age of four
years and older and injections are recommended for the new born and children
under four years of age.
Negotiations are being held with an international pharmaceutical company to have
MALAREX produced in Brazil one of the major sources of the raw material,
Peschiera Fuchsiaefolia, needed to produce MALAREX. Sufficient raw material
exists to ensure the supply required to meet and surpass our current sales
objectives and to meet expected demand for the foreseeable future. The current
product requires no more development and will be manufactured and sold in its
current state.
Mr. Motta, the V.P. of Research and Development, has undertaken, on his own
initiative, research and development programs relating to the Malaria virus and
enhancements to our current products. There is an agreement in understanding
that Mr. Motta will present to the company and allow the company first right of
refusal on any significant research and development matters. At this time, there
have been no significant matters presented to the company.
STRYCHNOS
As per the business statement of the company (see Business of Issuer, pg. 1), on
June 1, 1999 the company acquired from Mr. Silvio Rossi, one of the
co-discoverers of MALAREX, the patent rights to the anti-malarial agent
STRYCHNOS MYTROIDES (to be known as STRYCHNOS). The patent rights to STRYCHNOS
were solely owned by Mr. Rossi.
5
<PAGE>
At the present time, the company is not pursuing an active course of action with
regard to the STRYCHNOS patent. Since MALAREX is much closer to being brought to
the market, the Company is expending most of its resources on it. Once MALAREX
has been established in the market place and given the availability of funds,
the company intends to devote resources to actively develop STRYCHNOS.
The alkaloids of STRYCHNOS MYTROIDES are extracted by drying and converting the
stem barks of STRYCHNOS MYTROIDES into a powder. Exhaustive extraction is done
by repeated maceration and the resulting product is then processed to yield
crude tertiary alkaloids. Once the process has been completed the alkaloids of
STRYCHNOS MYTROIDES are used in combination with Chloroquine to enhance the in
vivo effectiveness of this drug against currently CQ-resistant strains of
malaria Plasmodim Falciparum. They also enhanced in vivo Chloroquine activity
against a resistant strain of Plasmodium Yoellii. (See Rasoanaiva P. et al in
Planta Medica: 13-16,1994).
Due to the serious resistance being currently encountered by Chloroquine, still
the most popular anti-malarial drug on the African continent, the ability of
STRYCHNOS in combination with Chloroquine to ameliorate some of the above
mentioned problem is a promising development.
The company intends, in the future, to continue research in this area both to
increase the efficacy of STRYCHNOS in combination with Chloroquine and to get
certification from the Department of Health of various African countries so as
to bring another weapon to bear in the fight against malaria.
MARKET SIZE
According to the World Health Organization (1999), malaria risks of varying
degrees exist in 100 countries and territories. Estimates of populations at risk
within these 100 countries total in excess of 2.3 billion people or 40% of the
world's population.
The WHO 1999 estimates 1.5-2.7 million deaths from malaria of which
approximately 850,000- 1,500,000 are caused by P. Falciparum. In addition to the
reported cases of contracted malaria, control programs dispense medication for
the prevention of malaria in the amount of a further 70 million plus complete
treatments annually.
The WHO estimates that for each clinical case reported, there exists at least
one, possibly two, that are unreported. Relative to the enormous number of
infected humans, it would be virtually impossible to eradicate the disease
altogether. If the disease was better controlled prevention, rather than
treatment, would become the dominant control factor.
Estimates of expenditures on treatment for the control and prevention of malaria
are in excess of US$10 Billion annually. The World Bank, per its figures,
allocates US$ 2.5 Billion to third world countries for malaria treatment.
DISTRIBUTION AND PRICING
.
Millenia's objective is to see that MALAREX is made available to as many people
as possible; as quickly as possible. In order to accomplish this goal, it is
Millenia's intention to initially focus on the production aspects of the product
and have it distributed where possible within already existing distribution
networks. Through an aggressive pricing strategy, Millenia intends to make
MALAREX available at prices that are less than the cost of other drugs currently
used in the treatment of malaria. This will facilitate MALAREX'S entry into a
marketplace that is price sensitive and should help it
6
<PAGE>
build sales volume due to its lower price. Even with pricing below that of the
competition, the Company should still earn a net profit that will allow future
growth potential.
Millenia intends to begin selling MALAREX, as soon as permission is gven by the
appropriate authorities in the countries in which the tests are being conducted,
even before any finalized patents are granted for MALAREX.
On January 9, 1998, the Company signed a 5 year non-exclusive worldwide
marketing agreement for MALAREX with L'Espoir du Millenaire Inc. The only
obligations under the contract are for the payment by L'Espoir to Millenia of
$30,000 annually for the 5 years and the obligation of L'Espoir to sell, at
least on average, $5 million of MALAREX for the fiscal years 2001-2003 in order
to retain this contract. This presupposes that permission will be granted by
countries to allow sales of MALAREX before 2001. Millenia believes , based on
its best estimates, that such permission will be granted before 2001 but has no
concrete basis to state this as a categorical fact. As such, should said
permission fail to materialize, the L`Espoir contract`s sales goal will be
extended to take this into consideration. The agreement also provides that
L'Espoir agrees to buy MALAREX or any other anti-malarial drug or agent, solely
from Millenia. The agreement further provides that Millenia has the sole
discretion in setting the price for MALAREX and L'Espoir is obligated to buy at
that price. Mr. Claude Villeneuve, a less than 5% shareholder of Millenia, is
the CEO and 100% owner of L'Espoir. However, since Mr. Villeneuve is neither an
officer or director and is unafilliated with Millenia excepts as a less than 5%
shareholder, he has no ability to influence the price of MALAREX.
Mr. Villeneuve has extensive international contacts and has assembled a team of
competent sales professionals and experts in the biomedical field to accomplish
this endeavor. The company believes that the above transaction is fair and has
been made at the prevailing market rates that would apply to any arms length
corporation involved in such a transaction.
On January 3, 1999, Millenia signed a non-exclusive world-wide agreement with
Richgold Corporation S.A. , a Panamanian corporation, for $1,465,000. Richgold
is to seek out potential buyers of Millenia`s regional licenses, enter
negotiations, together with Millenia with the perspective client and,
ultimately, successfully conclude the sale of said licenses, over the following
two years. These regional licenses allow the licensee to be the exclusive
purveyor of MALAREX in a specific region.
The purchaser of the license must agree to buy MALAREX , or any other
anti-malarial drug or agent, solely from Millenia and that Millenia has sole
discretion in setting the price of MALAREX.
Richgold`s sole obligation is to reach a minimum sales level of $2,500,000
during these 2 years and to make a determined effort to sell as many regional
licensing agreements as is possible and as is in the best interest of Millenia.
Since Richgold is a less than 10% shareholder and is unaffiliated with Millenia,
expect in this manner, it has no ability to influence the price of MALAREX.
Richgold has extensive contacts in South and Central America and will rely on
this network to fulfill its mandate. The company believes that the above
transaction is fair and has been made at the prevailing market rates that would
apply to any other arms length corporation.
The other $49,215 was paid to three Canadians (individuals) for miscellaneous
marketing and selling services.
As such, the Company does not see any conflicts of interest arising from its
marketing agreements.
PATENTS AND OTHER RIGHTS PURCHASED
Proprietary protection is an integral part of Millenia's strategy. The
commercial success of products, especially in the pharmaceutical industry, is
highly dependant upon their uniqueness being protected by patents. To this end
Millenia has not only purchased the patent rights and all other rights to
MALAREX and STRYCHNOS; it has also secured all research and development data and
notes pertaining to the above noted drugs from the commencement of initial
research to synthesis of the drug. In the future, as other products are
developed and come on line or are purchased, Millenia will take all necessary
steps to see that its product have the full measure of legal protection.
Furthermore; should there be any questions of infringement on its proprietary
rights, Millenia will be aggressive in asserting its legal position.
Currently, its 2 anti-Malarial drugs, MALAREX and STRYCHNOS, are protected under
patent applications filed covering their development. When the patent
applications were filed, the required documentation was filed along with it at
the appropriate patent offices. To the extent that Millenia is successful in
prosecuting its patent applications and they are accepted as valid patents, the
protection accorded is retroactive to the date of the original filings.
In 1997 Mr. Leonard Stella, through his professional contacts in the
medical/pharmaceutical industry, was introduced to the work of Mr. Sylvio Rossi
and Mr. Guiseppe Motta, co-discoverers of Voacamine as the core component of
MALAREX. Subsequent to meetings and discussions it was agreed that Millenia
would buy all rights to this product. This included but was not exclusive of
Italian Patent applications, PCT (international) Patent Applications, all
patents derived from the aforementioned, all priority rights and all commercial
and non-commercial rights without limitation. No residual rights belong to the
co-discoverers. An Italian patent Application registered MALAREX on March 26,
1998 for use as an anti-malarial agent and any secondary medicinal uses that may
be found in the course of testing or further research. PCT (International)
Patent Application for the same usage was filed on March 25, 1999. An Italian
Patent Application registered STRYCHNOS on June 1, 1999 for use as an
anti-malarial agent specifically, but not limited to, for usage as an adjuvant
to Chloroquine in fighting malaria. These three Patent applications have all
been approved for study of their technical merits. This is the first stage
acceptance culminating, hopefully, in the full patent being issued. After the
application has been accepted for study, the patent granting authority in that
jurisdiction do more in depth studies of the merit of the patent application
based on its scientific validity and test results to date. Once they feel that
the application has met the burden of proof for that particular patent request,
the actual patent is granted. This can take anywhere from 1 to 5 years to
achieve. While the company feels it is probable (high) that, at the end of the
process, patents will be issued, no assurance can be given that any patents will
ever be actually issued.
7
<PAGE>
TEST RESULTS
While not directly related to MALAREX, alkaloids of Vocagana, an extract of the
Voacamine family were shown to have a therapeutic effect upon some medical
maladies as early as 1958, specifically cardiovascular problems as seen in the
February 11, 1958 U.S. Patent 2823204.
Also, as reported in a study in the Journal of Natural Products Vol. 57 November
1994, under the auspices of the College of Pharmacy of the University of
Illinois at Chicago, Voacamine acted to enhance the growth inhibition of
multi-drug resistant cytotoxic cells present in certain malignant diseases such
as Hodgkins.
Currently, the testing of Voacamine, and the related costs of these tests, are
being performed by several governments, not for profit organizations and
research institutes with the sole goal of bringing to the market an effective
anti-malarial drug. Millenia has no funds and therefore is not, at present,
paying any of its employees nor any third party to have testing done on MALAREX.
In-Vitro testing of Voacamine, independently funded and performed by the
Institute of Superior Health of Rome, conducted by researchers Elena Federici,
Giovianna Palazzino and headed by Dr. Corrado Galeffi of the Institute of
Superior Health of Rome and Prof. Marcello Nicoletti of Department of Plant
Biology at La Sapeinza, University of Rome aided by Dr. Pierre Olliafo of
Unisante, Geneva, the WHO and Dr. L. Turchetto, as per the report of the
Institute of Superior Health in Rome 1997 with the result to reach Ic 50 level (
the level at which 50% of the cultured cells died, which is the benchmark for
such in-vitro tests). It only required a low dose of 179 micrograms per
milliliter of solution for chloroquine non resistant parasites and 282
micrograms per millilitre for chloroquine resistant parasites. Such a dose
indicates that MALAREX is very non-toxic.
In-Vitro tests were independently performed by Dr. Francesco de Chiara of the
Clinica Ospedale diAnchilo in Nampula, Mozambigue, funded by the Ministry of
Health and Wellbeing of Mozambigue, per his report of April 20, 1998 with
similar results to the Institute of Surgeon Health in Rome, in that the Ic50
level was reached at very low doses of Voacamine.
In the same report is an In-Vivo study of 74 Mozamicans with malaria who were
treated via sub- sutaneous injections using a suction and incubation method
(names of all patients are in his report). Clinical Results - within 24 hours
clinical symptoms of malaria (fever, vomiting, diarrhea, joint pains etc.)
disappeared and within 4 days the patients, having followed a 3 day treatment
regimen, showed a 90% rate of complete recovery.
In-Vivo tests were independently performed by Dr. Phillipe Rosoanaivo,
scientific director of the Malgache Institute of Applied Research in
Aniananarivo, Madagascar, under its own funding, on December 14, 1998 with the
report of the successful results being sent to Prof. Albert Rako To-Rat
Simamanga of the Institute of France. The report stated that it had tested
Voacamine at 10mg/kg, a very low dosage and had produced a 50% reduction in
parasitic levels.
_ As of February 28th, 2000 in-vitro testing was independantly funded and
performed by India's Directorate of Health were successfully completed.
- As of February 17th, 2000 in vitro testing was independantly funded and
performed by Cameroun's department of Health were successfully
completed.
8
<PAGE>
- As of February 27th, 2000 in-vitro testing was independantly funded and
performed by the Ministry of Health and Welfare of Equatorial Guinea
were successfully completed.
- Sucessful results mean that the dosage of the drug required to kill
50% of the parasitic cells was very low (very non toxic) and thus,
is, safe to be administered to human beings.
- Cameroun, as of February 27th, 2000 , in-vivo testing of camoeroun's
department of Health was successfully concluded. A phase 1 live trial
study at the laboratory of Parasitolgy and Immunology of the Hospital
Center of the University of YAOUNDE was performed with 30 patients. Of
these 18 patients or 60% were completely cured, all 18 in a 4 day
regimen of MALAREX. The other 12, having started in extremely high
parasitic levels 4,000 elements / mms, have significantly lower
parasitic levels than compared tp the beginning of the testing.
More complete information can be obtained by request of the institutions that
conducted the respective tests.
GOVERNMENT REGULATIONS
In order to safeguard their citizens, governments around the globe require
extensive proof that a new drug is completely safe, within statistical
parameters, before allowing it into the marketplace. Millenia, being cognizant
of the above and of its own responsibility to the public, has collated the
extensive laboratory and research data as well as the live trial tests for
MALAREX pursuant to its receiving the designation as a prescription drug.
Currently, MALAREX is in the middle of its clinical trial with the government of
India's Directorate of Health (see Plan of Operation). Having reviewed the
previous research data and test results, the Directorate of Health accepted
MALAREX for both in vitro and in vivo testing. The company has no definitive
time frame for MALAREX to receive permission to be sold to the public. Cameroun
and Equatorial Guinea (see Plan of Operation) are also in the process of running
clinical trials. A similar regimen is intended to be used with STRYCHNOS in
order to gain its certification at the appropriate time.
PRODUCT LIABILITY
Any drug or pharmaceutical product poses, by its nature, some level of risk.
Since drugs are widely disseminated among populations, all precautions must be
taken to ensure that the potential risk of any drug is kept to the barest
minimum. Since MALAREX and STRYCHNOS are all natural products and not chemically
produced, their potentially damaging side effects are minimized. This does not
mean that no side effects might occur, even with the most rigorous testing
standard applied, but rather that by their nature these 2 compounds are
inherently less susceptible. This being noted, once the product is approved for
use as a prescription drug the Company intends to take out appropriate liability
and product insurance with a major casualty insurer commensurate with the
statistical risk factors.
Acquisitions
On May 29, 2000, the company acquired thirty five million seven hundred thousand
(35,700,000) shares of SWORD COMP-SOFT CORP., this being 51% of SWORD's
authorized capital, at a cost of five million (5,000,000) common shares, valued
at the average thirty date trading range (OTC other) of $1.50 or seven million
five hundred thousand dollars ($7,500,000) and five million warrants
(5,000,000), entitling the registered holder thereof to purchase at any time
from that date for a period of three (3) years, one share of common stock at a
price of two dollars ($2). This transaction was at arms length with third
parties.
SWORD COMP-SOFT CORP. is an (ASP) Application Service Provider incorporated in
November 1998 specializing in the E-Healthcare sector.
9
<PAGE>
Employees
At the current time the following six officers of the company are its only
employees:
Mr. Leonard Stella - President \ Treasurer - Director.
Oversees all accounting functions, bank accounts, financial statements, cash
flow projections, etc. and is involved with the overall scientific coordination
as well as long term strategic planing - full time devoted to the Company -
Montreal resident.
Mr. Ronald La Penna - VP Personnel - Director.
Involved with future staffing planning, smooth runs of office functions -
Devotes 2 days a week to the Company - Montreal resident, president of Aqua
Boost - specialty water distributor.
Dr. Alain Soucy - Chairman of the Board of Directors - Director. Is
researching new projects and ideas and evaluating ongoing projects - chairs the
board meetings and is involved with the scientific planning - Donates 1 day a
week to the Company - Resident outside of the city of Montreal in Silleray.
Dr. George Haligua - VP Finance - Director.
Involved with long range financial planing and shareholder relations - donates 1
1\2 days a week to the Company - Montreal resident - President of Dasher
Computer Wholesale.
Mr Dominique Morisot - CEO - Director involved in the overall running
of the company, future strategic planning and specifically oversees the progress
of opening up new areas for MALAREX and the reception of their government
accreditation. Devotes full time - Resident of Geneva, Switzerland - Frequently
commutes to Montreal.
Mr. Thomas Bourne - Secretary
Responsible for minute book, corporate filings, shareholder lists etc. Devotes 1
day every 2 or 3 weeks as needed. Resident of Boca Raton, Florida and is a self
employed financial manager.
Mr. Guiseppe Motta - VP Research.
Does not receive a salary, but has a verbal agreement with the Company to allow
it first right of refusal on any significant research findings. Resident of
Turin, Italy - Plant Researcher at the University of Rome.
In addition to its six officers, as part of its lease, the Company has
access to secretarial services. None of the Company's employees belong to a
union and the Company believes that its relations with its employees are good.
The company knows of no conflict of interest between any of its officers and the
company.
Special Note Regarding Forward-Looking Statements
Some of the statements under "Plan of Operations," "Business"
and elsewhere in this registration statement are forward-looking statements that
involve risks and uncertainties. These forward-looking statements include
statements about our plans, objectives, expectations, intentions and assumptions
and other statements contained herein that are not statements of historical
fact. You can identify these statements by words such as "may," "will,"
"should," "estimates," "plans," "expects," "believes," "intends" and similar
expressions. We cannot guarantee future results, levels of activity, performance
or achievements. Our actual results and the timing of certain events may
10
<PAGE>
differ significantly from the results discussed in the forward-looking
statements. You are cautioned not to place undue reliance on any forward-looking
statements.
Item 2. Plan of Operation.
The following discussion should be read in conjunction with the financial
statements and related notes which are included elsewhere in this prospectus.
Statements made below which are not historical facts are forward-looking
statements. Forward-looking statements involve a number of risks and
uncertainties including, but not limited to, general economic conditions and our
ability to market our product.
The business objectives of Millenia are twofold. First and foremost is to
establish MALAREX as an accepted control agent for the treatment and prevention
of malaria throughout the world. Not only do we believe that MALAREX is an
effective anti-malarial drug, it will also be made available at prices that are
adapted to the realities of the third world market. The availability and pricing
of MALAREX, we believe, will ensure its acceptability and use in the fight
against malaria. To this end the company has entered into clinical trials of
MALAREX with the following three countries: India, Cameroun and Equatorial
Guinea
As previously noted in Business - Government Regulations, (pg. 9), the clinical
trials of the Ministry of Health of Cameroun have been successfully concluded.
While the Company believes that it will see sales within the next six months, as
there are no signed sales contracts and the company has not yet received its
final certification there is no basis for assurance that this will take place.
As such, the Company does not deem it proper to quantify a realistic estimate of
what such sales might be.
Millenia has adopted an extremely conservative sales forecast. In the face of
anti-malarial drug resistance, the need for more effective treatments will
continue to intensify. Once a network of local manufacturers and distributors
capable of producing and supplying MALAREX are in place, the demand for MALAREX
should increase commensurately.
It is estimated the demand for MALAREX will increase as it becomes one of the
accepted choices in the fight against malaria. Millenia has chosen to remain
conservative and has established a goal of capturing 2% ($200 million) of the
marketplace in five years. According to the company's internal estimates, based
upon it's knowledge of the industry, attaining this sales level will ensure the
viability and profitability of the Company for its shareholders. No assurance
can be given that the Company will meet its sales goals.
Secondly, Millenia is committed to ongoing research and development to expand
the efficacy of MALAREX and its derivatives in fighting infectious diseases. To
this end, the company has a verbal agreement with one of its officers Mr.
Guiseppe Bertelli Motta, VP of research and a co-discoverer of MALAREX whose
profession is botanical research, that it will have the first right of refusal
on any of his significant research findings. As cash flow improves, further
funding will be committed to research and development.
As an integral part of this development, Millenia hopes to establish long term
relationships with other major organizations such as Rotary Against Malaria
(RAM), World Health Organization and the Centers for Disease Controls. It is
through these relationships that Millenia feels that they can best support the
efforts of such organizations to solve the problem of malaria by building an
infrastructure necessary to control this disease.
11
<PAGE>
As the Company has not yet begun to sell the Product, it is difficult for
management to evaluate the growth curve of Product sales. However, given the
potential market size and the need for viable and effective drugs, the Company
believes that it will not have a problem generating sales thereby creating
positive cash flow once the Product is approved.
The Company intends to use the Internet for advertising as that currently allows
the greatest visibility for very small costs. In fact, the Company believes that
it will be able to obtain free access on certain websites looking for products
such as the Company's.
For the fiscal year ended November 30, 1998. The cost of the patent and
commercial rights for Malarex, its anti-malarial agent acquired in January of
1998, was $747,300.The company had Research and Development costs of $218,515
(net - 8% imputed interest) for the acquisition of the research data related to
the development of MALAREX. ($218,515 net 8% imputed interest) ( See item 7,
Certain Relationships and Related Transactions) Premesis Rent came to $61,250
and $14,150 was paid to clerical help and for the use of office equipment at its
leased premises. The company had $122,000 of overseas Travel expenses in its
initial year of operation. Selling, General and Administration expense came to
$292,000 including $15,200 of depreciation.
For the fiscal year ended November 30, 1999. The cost of the patent and
commercial rights for Strychnos, acquired in June 1999, was $258,527. The
company had no outlays for Research and Development. As previously stated,
Research and Development is limited to having the right of first refusal on any
significant research findings of its V.P. of Research, Mr. Motta. The company
paid $1,514,215 to four companies/individuals via issuance of 1,111,220 shares
of stock for marketing services. (See Item 10 Recent Sales of Unregistered
Securities). Premises Rent came to $61,200 and $14,150 was paid to clerical help
and for the use of office equipment at its leased premises. (In 1999 the $14,150
was included in the line of Selling, General and Administrative expenses).
Overseas Travel expenses were nil.
For the fiscal year ending November 30, 2000 the company is estimating the
following costs:
1. Marketing: None.
2. Research and Development: No cost outlays expected - first right of
refusal on the research of Mr. Motta is the only current research
being undertaken.
3. Premises: Rent - $61,250 as in previous years.
4. Clerical Help and office Equipment Expenses: $14,150 as in previous
years (to be included in Selling, General and Administration
expenses).
5. Overseas Travel expenses: $100,000 as the company has planned trips
to Brazil (its manufacturing and raw material base), India and
Africa.
6. Selling, General and Administration: $130,000 as in the previous
year (this will include $14,000 of depreciation expense).
There is currently insufficient funds to adequately provide for the Company's
needs over the next twelve months. Additional capital and/or borrowings will be
necessary in order for the Company to continue in existence until attaining and
sustaining profitable operations. Management has continued to develop a
management team, maintain reporting compliance and establish long term
relationships with other major organizations to develop and distribute the
product Malarex. Management anticipates generating revenue through the sales of
Malarex during the next fiscal year. The major shareholder's of the organization
have committed to find the operations of the organization during the next fiscal
year until the organization can generate sufficient cash flow from operations to
meet current operating expenses and overhead.
The Company intends to continue conducting product research and development via
its previously noted agreement with Mr. Motta. The Company will, in the future,
retain marketing and public
12
<PAGE>
relations consultants as necessary, and hire support staff when warranted by its
sales volume on an as needed basis.
Item 3. Description of Property.
The Company leases its corporate offices at 4055 St. Catherine Street, Suite
142, Montreal, Quebec at annual rental of US $79,325 pursuant to the terms of a
five year lease commencing December 27, 1997. The lease also provides for a five
year renewal option at an annual rent of US $83,291.
Item 4. Security Ownership of Certain Beneficial Owners and Management.
The following table sets forth, as of December 31, 1999, certain information
concerning the ownership of the Company's Common Stock by: (i) each person who
is known by the Company to own beneficially 5% or more of the outstanding shares
of common stock; (ii) each of the Company's directors; and (iii) the name of
each executive officer, both in respect to the number of shares owned by each
person and the percentage of the outstanding shares represented thereby that
also sets forth such information for directors and executive officers as a group
(see item 6 (b) and (c)). Except as otherwise indicated, the stockholders listed
in the table have sole voting and investment powers with respect to the shares
indicated. Pursuant to the rules of the Securities and Exchange Commission,
shares of common stock which an individual or a group has a right to acquire
within 60 days of December 31, 1999 pursuant to the exercise of presently
exercisable or outstanding options, warrants or conversion privileges are deemed
to be outstanding for the purpose of computing the percentage ownership of such
individual or group, but are not deemed to be outstanding for the purpose of
computing the percentage ownership of any other person shown in the table.
Information with respect to beneficial ownership is based upon the shareholder
list provided by the Company's transfer agent.
Name and Address Amount and Nature
of Beneficial Owner of Beneficial Owner Percent of Class
Tom Bourne 1,000,000 8.9
7755 Texas Trail
Boca Raton, FL
Pierre & Finane 1,000,000 8.9
Pierre Jean Mercier
38-A De Malagnon
CH 1108 Geneva
Switzerland
Andrew Gaudet 1,000,000 8.9
P.O. Box 1492
Boca Raton, FL
Richgold Corporations SA 1,075,000 9.6
Reuben Armanta
P.O. Box 1754 Panama CA
Republic of Panama (1)
Skyline Holdings Inc. 900,000 8.0
Roger Levesque
13
<PAGE>
4055 St. Catherine West
Suite 133, Westmount
Terotex Enterprises 750,000 6.7
Jean Vincent Roy
4055 St. Catherine,
Suite 132
Montreal
George Haligua (2) (3) 170,000 1.5
Ronald Lapenna (2) (3) 80,000 *
Dominique Morisot (2) (4) 50,000 1.3
Giuseppe B. Motta 25,000 *
Leonard Stella (3) (4) 70,000 *
Alain Soucy (6) 100,000 *
All Directors and
Executive Officers as
a Group (5 persons) (5) 495,000 4.4
-------------------
* Less than 1%
(1) Includes 100,000 shares held by an affiliated entity.
(2) Uses Company address.
(3) Includes 50,000 currently exercisable stock options.
(4) Consists of currently exercisable stock options.
(5) Includes 220,000 currently exercisable stock options.
(6) Includes 100,000 stock options
Item 5. Directors, Executive Officers, Promoters and Control Persons.
(a) Directors and Executive Officers.
Name Age Position
Leonard Stella 38 President/Treasurer - Director
--------
Ronald Lapenna 56 VP Personnel - Director
--------
Alain Soucy 65 Chairman of the Board of
Directors - Director
--------
George Haligua 42 VP Finance - Director
--------
Dominique Morisot 48 CEO - Director
--------
Thomas Bourne 55 Secretary
Guiseppe Bertelli Motta 56 VP Research, Board Advisory Committee
14
<PAGE>
Dr. Alain Soucy, Chairman of the Board of Directors. Dr. Soucy received
his Bachelor in Engineering from Laval University and his Doctorate in
Engineering from Universite de Grenoble in France in 1963. From 1984 to 1988 he
headed up the Institute of Superior Technology. From 1988 through 1998 he was
the director general of INRS (Institut National de la Recherche Scientifique) a
broad discipline based research institute where he oversaw a rise in both
research income and graduate student participation. The INRS is Quebec's leading
research institute in the following nine scientific areas: Water, Earth, Marine,
Energy and Material, Telecommunications, Urban Studies, Social, Health and
Biotechnology. Concurrent with this posting, Dr. Soucy was also the director
general of the Armond Frappier Institute, one of the leading pharmaceutical
research facilities in Canada. Among his other projects is overseeing
(1975-1984) all programs and environmental studies associated with the James Bay
hydro electric development in Northern Quebec, one of the world's largest
electricity generating facilities. He has sat on over two dozen Boards of
Research Institutes and is a member of a dozen professional associations.
M. Leonard Stella, President/Treasurer, Director. Mr. Stella has a
Bachelor of Arts from McGill University, and received his Masters of Arts in
Administration from Concordia University in 1986. In 1987 Mr. Stella founded and
operated a residential and commercial property developer, Dominion Certified
Development. In 1991, he founded Trans-Immobilia, a residential property company
that he continues to run. In 1998 he became one of the founding partners and
holds the position of president and treasurer of the Company.
Mr. Dominique Morisot, CEO, Director. Mr. Morisot has extensive
contacts through Europe and Asia. Although born in France, he is a long term
resident of Geneva, and for 30 years has consulted to many companies overseeing
the marketing and development of new territories as well as selling of products
and projects in various lines of business. He brings to the Company an extensive
knowledge of the overseas marketplace, and is an important source of information
for potential products for the Company.
Dr. George Haligua, VP Finance, Director. Dr. Haligua received his
Bachelor of Commerce from Haute Etude Commercial in Paris in 1977 and his
Doctorate in Finance from l'Institue de Technologie in Basil, Switzerland in
1979. From 1980-82 he was a Vice-President at the Banque Nationale de Paris.
During his tenure at Hunter Financial Group (1983-86), an Investment Bank
headquartered in Calgary, Canada, he was promoted from 1st Vice-President to
running the company as President and CEO. From 1986-91, he was the President and
CEO of United Financial Corp. one of Canada's leading investment groups and fund
managers operating out of their Vancouver office. Since 1992 he has founded and
runs several computer and computer related corporations principally Dasher
Computer Wholesalers of Toronto, Ontario.
Mr. Ronald Lapenna, VP Personnel, Director. Mr. Lapenna has extensive
experience in the field of human resources and administration having served in
this capacity for various levels of the Canadian Government, both federal and
municipal. At the municipal level from 1980-1990, Mr. Lapenna created and
managed the first integrated public security service for one of Montreal's top
municipalities. At the federal level, from 1991-1993, he worked under the
Minister of Transportation in creating specialized programs for airport
personnel. Since 1993 he has run his own consulting firm, Penna & Associates. In
1999 he took on the added responsibility as President of Aqua Boost, a
progressive manufacturer of specialized and bottled waters.
Mr. Thomas Bourne, Secretary. Mr. Bourne is a professional financial
manager and advisor, having received his accreditation as a CA, a member of the
Order of Chartered Accountants of Canada. He has had vast experience in dealing
with the Banking and Investment circles having
15
<PAGE>
been for many years the Chief Investment Officer of one of Ontario, Canada's
largest Credit unions. Over the past ten years, he has shifted his base of
operations to the state of Florida where he practices in Boca Raton, as an
independent financial consultant.
Mr. Guiseppe Bertelli Motta, VP Research, Board Advisory Committee. Mr.
Motta is one of the co-discoverers of the use of Voacamine as the active
ingredient in Malarex, Millenia's premier anti-malarial drug. As a leading
Italian botanical researcher, Mr. Motta together with Professor Silvio Rossi did
the painstaking research required in taking a natural compound and having it's
efficacy as a pharmaceutical agent bourne out. Mr. Motta, using his expert
knowledge of the wide spectrum of flora and fauna, is aggressively working on
several extracts as the basis of other natural remedies both for malaria and
other infectious diseases. Mr. Motta has been involved with the University of
Roma as a researcher for more than the past 5 years.
(b) Significant Employees
None
(c) Family Relationships
There are no family relationships among directors or executive officers of the
Company.
(d) Involvement in Certain Legal Proceedings.
None.
Item 6. Executive Compensation.
(a) General
Commencing December 1, 1999, the Company has agreed to pay Dr. Alain Soucy, its
Chairman of the Board of Directors, an annual salary of $36,000.
(b) Summary Compensation Table of Directors
SUMMARY COMPENSATION TABLE
Name and Long-term
Principal Position Year Salary Bonus Compensation: Options (1)
------------------ ---- -------- ----- -------------------------
Alain Soucy 1999 0 0 100,000 options(1)
Chairman
Leonard Stella 1999 0 0 210,000 options(2)
President, Treasurer
& Director
Dominique Morisot 1999 0 0 150,000 options(2)
CEO
& Director
Ronald Lapenna 1999 0 0 50,000 options(3)
VP-Personnel
& Director
George Haligua
VP Finance
& Director 1999 0 0 50,000 options(3)
16
<PAGE>
(1) Exercisable commencing August 30, 2000 at $.30 per share until December
31, 2003.
(2) Vest equally over 3 years commencing January 29, 2000. Exercisable at
$1.50 per share until December 31, 2003.
(3) Vested on January 29, 2000. Exercisable at $1.50 per share until
December 31, 2003.
(c) Options/SAR Grants Table
OPTION GRANTS IN LAST FISCAL YEAR
(Individual Grants)
<TABLE>
<S> <C> <C> <C> <C>
% of Options Exercise Price
Name Number of Options Granted (1999) (per share) Expiration
---- ----------------- -------------- ----------- ----------
Alain Soucy 100,000 17.85% $.30 12/31/03
Leonard Stella 210,000 37.50% $1.50 12/31/03
Dominique Morisot 150,000 26.78% $1.50 12/31/03
Ronald Lapenna 50,000 8.93% $1.50 12/31/03
George Haligua 50,000 8.93% $1.50 12/31/03
</TABLE>
(d) Aggregated Option/SAR Exercises and Fiscal Year End Option/SAR Value Table
None
(e) Long Term Incentive Plan ("LTIP") Awards Table
None
(f) Compensation of Directors
No Director receives any compensation for serving on the Board.
(g) Employment Contracts and Termination of Employment, and Change-in-Control
Arrangements
The Company has no employment contracts with any of its executive officers. Dr.
Alain Soucy serves as Chairman of the Company for $36,000 annually. There are no
provisions for cash compensation to be paid to any executive officer or director
of the Company now, or upon the termination of their services. As indicated
above, certain officers received stock options as compensation.
17
<PAGE>
(h) Report on Repricings of Options/SARs
None.
Item 7. Certain Relationships and Related Transactions.
The Company issued, on June 15, 1998, an unsecured long term note in the
principal amount of $218,515 (net - 8% imputed interest) bearing annual payments
of $44,400 for five years, a final payment of $33,600 and maturing on June 15,
2004. The Note is to Guiseppe Motta and Silvio Rossi. Mr. Motta is an officer of
the Company. The balance due on November 30, 1999 was $192,830.
The company issued, on March 30, 1998 a promissory note to Claude Villeneuve, a
shareholder, which is unsecured and bears interest in the amount of 8% per
annum. The principal amount of this loan is $946,093. The amount at November 30,
1999 including interest is $1,043,464 and has no maturity date.
The company issued on June 1, 1999, an unsecured long term note in the principal
amount of $180,389 (net - 8% imputed interest) with no fixed annual repayments
but fully payable by May 31, 2002. This note was issued to Mr. Silvio Rossi.
The company signed an agreement, on May 31, 1998, to reimburse Claude
Villeneuve, a shareholder, for auto expenditures at a rate of $1,040 per month.
On January 9, 1998, the company entered into an agreement with L'Espoir Du
Millenaire Inc. whereby L'Espoir Du Millenaire Inc. has a marketing and
distributor rights for the product Malarex. This non exclusive worldwide
agreement is for 5 years and requires L'Espoir Du Millenaire Inc. to make annual
payments of $30,000 to the Company for the rights. The agreement also allows for
renewal for an additional 5 years provided that certain sales quotas have been
met. L'Espoir Du Millenaire Inc. is owned Mr. Claude Villeneuve, a shareholder
of the Company. The agreement also provides that L'Espoir agrees to buy MALAREX
or any other anti-malarial drug or agent, solely from Millenia. Mr. Claude
Villeneuve, a shareholder owning less than 5% of the total outstanding shares of
the company, agreed to provide unsecured debt, to aid the company's cash flow
problem, at an 8% rate of interest. Mr Villeneuve has extensive international
contacts and has assembled a team of competent sales professionals and experts
in the biomedical field to accomplish this endeavor. The company believes that
all the above transactions are fair and have been made at the prevailing market
rates that would apply to any arms length corporation involved in such
transactions.
On June 15, 1998 the company signed a purchase agreement with Mr. Silvio Rossi
and Mr. Giuseppe Motta to acquire all of the research data, without any
exception, involved in the development of MALAREX for $300,000 gross ($218,515
net with 8% imputed interest). The agreement called for a payment of $44,000 in
the 1st year and further payments of $44,000 a year for 5 years with a final
payment of $33,6000 in the 6th year. This entitles Millenia to, but is not
exclusive of, all intellectual rights, commercial rights and their derivations
etc. The agreement also contains a clause that does not allow Mr. Motta and Mr.
Rossi to duplicate any of this data for 15 years. The company believes that this
is a fair business transaction and does not create a conflict of interest with
any of the parties involved. Mr. Motta is an officer of the company.
Item 8. Legal Proceedings
None
18
<PAGE>
Item 9. Market Price for Common Equity and Related Stockholder Matters.
(a) Market Information
The Company's Common Stock is currently quoted for trading on the OTC Bulletin
Board under the symbol MLHP. The following table sets forth the range of
quarterly, high and low sale prices for the Company's Common Stock from the
inception of quotation during the fourth quarter of 1998 and for 1999. The
quotations represent inter-dealer quotations without adjustment for retail
markups, markdowns or commissions, and may not necessarily represent actual
transactions.
Common Stock
High Low
1998
Fourth Quarter (initial trading) $1.50 $.25
1999
First Quarter $1.75 $.50
Second Quarter $2.00 $1.12
Third Quarter $2.50 $.75
Fourth Quarter $1.45 $.43
Of the 11,211,220 shares of common stock outstanding,
4,000,000 are currently subject to the resale restrictions and limitations of
Rule 144. In general, under Rule 144 as currently in effect, subject to the
satisfaction of certain other conditions, a person, including an affiliate, or
persons whose shares are aggregated with affiliates, who has owned restricted
shares of common stock beneficially for at least one year is entitled to sell,
within any three-month period, a number of shares that does not exceed 1% of the
total number of outstanding shares of the same class. In the event the shares
are sold on an exchange or are reported on the automated quotation system of a
registered securities association, you could sell during any three-month period
the greater of such 1% amount or the average weekly trading volume as reported
for the four calendar weeks preceding the date on which notice of your sale is
filed with the SEC. Sales under Rule 144 are also subject to certain manner of
sale provisions, notice requirements and the availability of current public
information about us. A person who has not been an affiliate for at least the
three months immediately preceding the sale and who has beneficially owned
shares of common stock for at least two years is entitled to sell such shares
under Rule 144 without regard to any of the limitations described above.
19
<PAGE>
(b) Holders
As of December 31, 1999, there were 180 holders of the Company's common stock.
(c) Dividends
The Company has had no earnings to date, nor has the Company declared any
dividends to date. The payment by the Company of dividends, if any, in the
future, rests within the discretion of its Board of Directors and will depend,
among other things, upon the Company's earnings, its capital requirements and
its financial condition, as well as other relevant factors. The Company has not
declared any cash dividends since inception, and has no present intention of
paying any cash dividends on its Common Stock in the foreseeable future, as it
intends to use earnings, if any, to generate growth.
Item 10. Recent Sales of Unregistered Securities.
In December 1997 the company sold 4,000,000 shares of Founders stock at $
0.00505 for a total of $20,200. In February 1998 the Company sold 6,100,000
shares of Common Stock at a price of $.07 per share. The company settled on this
price after weighing its need for initial funding, inherent risk of all new
ventures and funds being paid for shares of this type of enterprise. Also issued
were 6,100,000 warrants exercisable at $0.09 per share until May 31, 2001. These
shares were sold and issued pursuant to the exemption from registration
contained in Regulation D, Rule 504.
In March 1999 the Company issued 1,111,220 shares of Common
Stock in settlement of marketing agreements established with organizations and
individuals for their services which included the marketing of the Company and
its product Malarex globally. The total marketing cost was $1,514,215.The
company's share value on that date was trading on the OTC Bulletin Board at
$1.3627. The transaction was at arm's length with third parties. These shares
were issued pursuant to the exemption contained in Regulation S of sales to non
- U.S. persons.
Item 11. Description of Securities.
(a) Common or Preferred Stock
The Company is authorized to issue 70,000,000 shares of Common Stock,
$0.0001 par value, of which 11,211,220 shares were issued and outstanding as of
the date hereof. Each outstanding share of Common Stock is entitled to one (1)
vote, either in person or by proxy, on all matters that may be voted upon the
owners thereof at meetings of the stockholders.
The holders of Common Stock (i) have equal ratable rights to dividends
from funds legally available therefor, when and if declared by the Board of
Directors of the Company; (ii) are entitled to share ratably in all of the
assets of the Company available for distribution to holders of Common Stock upon
liquidation, dissolution or winding up of the affairs of the Company; (iii) do
not have preemptive, subscription or conversion rights, or redemption or sinking
fund provisions applicable thereto; and (iv) are entitled to one non-cumulative
vote per share on all matters on which stockholders may vote at all meetings of
stockholders.
Holders of Shares of Common Stock of the Company do not have cumulative
voting rights, which means that the individuals holding Common Stock with voting
rights to more than 50% of eligible votes, voting for the election of directors,
can elect all directors of the Company if they so choose and, in such event, the
holders of the remaining shares will not be able to elect any of the Company's
directors.
20
<PAGE>
(b) Debt Securities.
The Company has not issued any debt securities to date.
(c) Other securities to be Registered
None.
Item 12. Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation Law, as amended, authorizes the
Company to Indemnify any director or officer under certain prescribed
circumstances and subject to certain limitations against certain costs and
expenses, including attorney's fees actually and reasonably incurred in
connection with any action, suit or proceeding, whether civil, criminal,
administrative or investigative, to which a person is a party by reason of being
a director or officer of the Company if it is determined that such person acted
in accordance with the applicable standard of conduct set forth in such
statutory provisions. The Company's Certificate of Incorporation contains
provisions relating to the indemnification of director and officers and the
Company's By-Laws extends such indemnities to the full extent permitted by
Delaware law.
The Company may also purchase and maintain insurance for the benefit of any
director or officer which may cover claims for which the Company could not
indemnify such persons.
Item 13. Financial Statements.
The financial statements are included at the end of this Registration Statement,
prior to the signature page.
Item 14. Changes In and Disagreements With Accountants on Accounting and
Financial Disclosure.
On February 23, 1999, the Company dismissed Francesca Albano its auditor for the
fiscal year ended November 30, 1998. Their report did not contain an adverse
opinion or disclaimer of opinion nor was it modified as to uncertainty, audit
scope or accounting principles. The decision to change accountants was made by
the Board of Directors based upon the Company's decision to pursue becoming a
reporting company and the need to appoint independent auditors qualified to
submit reports for filing with the SEC. There were no disagreements with the
former auditor which if not resolved would have caused it to make reference to
such disagreement in connection with its report. On March 2, 1999 the company
engaged Mark Cohen C.P.A to be its new auditor with whom the company had not had
any prior consultations.
Item 15. Financial Statements and Exhibits.
(a) List of Financial Statements filed herewith.
Millenia Hope Inc
(A company in the development stage)
Independent Auditors' Report
21
<PAGE>
Balance Sheet (11/30/99 and 11/30/98) Statement of Income (Years ended
11/30/99 and 11/30/98) Statement of Shareholders' Equity (Year ended
11/30/99 and 11/30/98) Statement of Cash Flows (Years ended 11/30/99
and 11/30/98) Summary of Significant Accounting Policies (year ended
11/30/99) Notes to the Finance Statements (year ended 11/30/99)
(b) List of Exhibits.
3.1 Certificate of Incorporation
3.2 By-Laws
4.1 Form of Stock Certificate*
10.1 Purchase Agreement for Voacamine
10.2 Purchase Agreement for Research Data
10.3 Purchase Agreement for Strychonos
10.4 Licensing Agreement with L'Espoir Du Millenaire Inc.
10.5 Service Agreement with Richgold Corporations SA
10.6 Lease Agreement
10.7 Auditors Opinion 1998
27 Financial Data Schedule
--------------------------
*To be filed by Amendment
22
<PAGE>
Mark Cohen C.P.A.
1772 East Trafalgar Circle
Hollywood, Fl 33020
(954) 922 - 6042
INDEPENDENT AUDITORS' REPORT
Board of Directors
Millenia Hope Inc.
We have audited the accompanying balance sheet of Millenia Hope Inc. (a company
in the development stage) as of November 30, 1999 and the related statements of
operations, shareholders' equity (deficiency) and cash flows for the year ended.
These financial statements are the responsibility of the Company's management.
Our responsibility is to express an opinion on these financial statements based
on our audits. The financial statements of Millenia Hope Inc. as of November 30,
1998 were audited by other auditors whose report dated January 27, 1999,
expressed an unqualified opinion on those statements.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Millenia Hope Inc. at November
30, 1999, and the results of its operations and its cash flows for the year then
ended, in conformity with generally accepted accounting principles.
The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. As discussed in Note 4 to the
financial statements, the Company has experienced an operating loss that raises
substantial doubt about its ability to continue as a going concern. Management's
plans in regard to these matters are also described in Note 6. The financial
statements do not include any adjustments that might result from the outcome of
this uncertainty.
/s/Mark Cohen
Mark Cohen C.P.A.
A Sole Proprietor Firm
Hollywood, Florida
January 21, 2000
<PAGE>
MILLENIA HOPE INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
BALANCE SHEET
NOVEMBER 30, 1999 AND 1998
Assets
1999 1998
Current Assets
Cash and cash equivalents $ 3,933 $ 21,000
Total current assets 3,933 21,000
Property and equipment, net 46,236 60,800
Total assets 50,169 81,800
============= =======
Liabilities and Shareholder's Equity
Current Liabilities
Accounts payable 165,200 256,700
Current portion of long term debt
(net of discount) 88,800 44,400
Notes payable (principally related parties)
(net of discount) 1,223,853 692,000
Other current liabilities 11,450 -
Total current liabilities 1,489,303 993,100
Long-term debt, less current portion
(net of discount) 104,031 134,850
Shareholder's Equity
Common Stock, $.0001 par value; authorized 1,121 1,010
70,000,000 shares; issued and outstanding
11,211,220 in 1999 and 10,100,000 in 1998
Paid in Capital 1,960,294 446,190
Deficit accumulated during the development
stage (3,504,579) (1,493,350)
Total Shareholder's Equity (1,543,164) (1,046,150)
Total liabilities and shareholder's equity $ 50,169 $ 81,800
=============== =========
Read the accompanying summary of significant accounting policies and notes to
financial statements, both of which are an integral part of this financial
statement.
<PAGE>
MILLENIA HOPE INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
STATEMENT OF INCOME
FOR THE YEARS ENDED NOVEMBER 30, 1999 AND 1998
FROM INCEPTION (DECEMBER 24, 1997) THROUGH NOVEMBER 30, 1999
<TABLE>
<S> <C> <C> <C>
Inception
(December 24, 1997)
Years Ended through
November 30, 1999 November 30, 1998 November 30, 1999
----------------------------------------------------------------------------
Revenue:
Licensing fees $ 27,500 $ - $ 27,500
Operating expenses:
Marketing 1,514,215 - 1,514,215
Patent Rights 258,527 747,300 1,005,827
Other Development Costs - 218,515 218,515
Rent 61,250 76,400 137,650
Travel - 122,000 122,000
Selling, general and
administrative expenses 120,003 292,000 412,003
------------------- ------------------ -------------------
Total operating expenses 1,953,995 1,456,215 3,410,210
Loss before other income
(expense) (1,926,495) (1,456,215) (3,382,710)
Other income (expense):
Interest expense (84,734) (37,135) (121,869)
------------------- ------------------ -------------------
Total other income
(expense) (84,734) (37,135) (121,869)
Net Loss (2,011,229) (1,493,350) (3,504,579)
=================== ================== ===================
Basic weighted average common
shares outstanding 11,052,384 10,100,000 10,730,000
=================== ================== ===================
Basic Loss per common share $ (0.1820) $ (0.1479) $ (0.3266)
=================== ================== ===================
</TABLE>
Read the accompanying summary of significant accounting policies and notes to
financial statements, both of which are an integral part of this financial
statement.
<PAGE>
MILLENIA HOPE INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
STATEMENT OF SHAREHOLDERS' EQUITY
FROM INCEPTION (DECEMBER 24, 1997) THROUGH NOVEMBER 30, 1999
<TABLE>
<S> <C> <C> <C> <C> <C> <C>
Accumulated
Deficit during Total
Common Paid in Development Shareholders'
Shares Amount Capital Stage Equity
---------------- ------------ ------------ -------------- ---------------
Balance, beginning December 24, 1997: - $ - $ - $ - $ -
Proceeds from December 1997 private
placement 4,000,000 400 19,800 20,200
Proceeds from February 1998 private
placement 6,100,000 610 426,390 427,000
Net loss year ended November 30, 1998 (1,493,350) (1,493,350)
---------------- ------------ ------------- -------------- ---------------
Balance at November 30, 1998 10,100,000 1,010 446,190 (1,493,350) (1,046,150)
March 20, 1999 settlement of
marketing contracts 1,111,220 111 1,514,104 1,514,215
Net loss year ended November 30, 1999 (2,011,229) (2,011,229)
---------------- ------------ -------------- -------------- ---------------
Balance, ending November 30, 1999: 11,211,220 $ 1,121 $1,960,294 $(3,504,579) $(1,543,164)
================ ============ ============== ============== ===============
</TABLE>
Read the accompanying summary of significant accounting policies and notes to
financial statements, both of which are an integral part of this financial
statement.
<PAGE>
MILLENIA HOPE INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
STATEMENT OF CASH FLOWS
FOR THE YEARS ENDED NOVEMBER 30, 1999 AND 1998
FROM INCEPTION (DECEMBER 24, 1997) THROUGH NOVEMBER 30, 1999
<TABLE>
<S> <C> <C> <C>
Inception
(December 24, 1997)
Years Ended through
1999 1998 November 30, 1999
-------------- ------------- ---------------------
CASH FLOWS FROM OPERATING ACTIVITIES: $(2,011,229) $(1,493,350) $ (3,504,579)
Net Income (Loss) 14,564 15,200 29,764
Adjustments to reconcile net income
(loss) to net cash used in operating
activities:
Depreciation and amortization 1,514,215 - 1,514,215
Issuance of stock for marketing
services - -
Issuance of note for patent rights 13,581 179,250 192,831
Issuance of note for other
development costs (80,050) 256,700 176,650
-------------- ------------- -------
Net cash provided by (used in)
operating activities (548,919) (1,042,200) (1,591,119)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of Property and equipment - (76,000) (76,000)
-------------- ------------- -------
Net cash provided by (used in)
investing activities (0) (76,000) (76,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from:
Notes payable, principally related
parties (net of discount) 531,853 692,000 1,223,853
issuance of stock - 447,200 447,200
-------------- ------------- ---------
Net cash provided by (used in)
financing activities: 531,853 1,139,200 1,671,053
-------------- ------------- ---------
Net increase (decrease) in cash
and cash equivalents (17,067) 21,000 3,933
Cash and cash equivalents, beginning
of period 21,000 - -
-------------- ------------- ---------
Cash and cash equivalents, end of period $ 3,933 $ 21,000 $ 3,933
============== ============= =========
</TABLE>
Read the accompanying summary of significant accounting policies and notes to
financial statment, both of which are an integral part of this financial
statement.
<PAGE>
MILLENIA HOPE INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
NOTES TO THE FINANCIAL STATEMENTS
Years Ended NOVEMBER 30, 1999 AND 1998
1. Organization and business
Millenia Hope Inc. was incorporated in the State of Delaware on
December 24, 1997. Through its acquisition of the patent rights for
Malarax and Strychnos, the Company participates in the treatment and
prevention of malaria. Although there is no assurance that the patent
will ever be issued, management feels the likelihood of issuance is
probable (high) due to the positive test results attained in clinical
studies.
2. Concentrations of credit risk
Financial instruments which potentially subject the Company to
concentrations of credit risk consist principally of cash, cash
equivalents and accounts receivable. The credit risk associated with
cash and cash equivalents is considered low due to the credit quality
of the financial institutions. The Company maintains, when
appropriate, an allowance for uncollectible receivables. Therefore, no
additional credit risk beyond amounts provided for collection losses
is believed inherent in the Company's receivables and to date have
been within management's expectations.
3. Details of financial statement components
1999 1998
---- ----
Property and Equipment:
Furniture and Fixtures $ 15,900 $ 15,900
Leasehold Improvements 60,100 60,100
------ ------
76,000 76,000
Accumulated Depreciation/Amortization 29,764 15,200
------ ------
Property, and Equipment, net $ 46,236 $ 60,800
Other Current Liabilities:
Deferred Revenue $ 2,500 $ -
Accrued Expenses 8,950 -
----- ------
$ 11,450 $ -
4. Note Payables:
Note Payable - Silvio Rossi $180,389 $ -
unsecured, discounted for 8%
imputed interest, maturing
May 31, 2002
Related Party:
Promissory Note Payable -
C. Villenueve, 1,043,464 692,000
a shareholder, unsecured, interest ---------- ---------
at 8% $ 1,223,853 $ 692,000
per annum, no maturity date.
5. Long-term debt
Promissory Note - Giuseppe Motta $ 192,831 $ 179,250
and Silvio Rossi, unsecured,
discounted for 8%
Imputed interest; annual
payments of $44,400 for 6
years and a final payment of
$33,600
Less current portion of long term
debt 88,800 44,400
------------ ---------
$ 104,831 $ 134,850
The note matures July 14, 2005.
<PAGE>
6. Going Concern:
The accompanying financial statements have been prepared assuming the
Company will continue as a going concern. The company reported a net
loss of $2,011,229 for the year ended November 30, 1999 and has
reported net losses of $3,504,579 from inception (December 24, 1997)
to November 30, 1999. As reported on the statement of cash flows, the
Company incurred negative cash flows from operating activities of
$1296,219 for the year ended November 30, 1999 and has reported
deficient cash flows from operating activities of $1,591,119 from
inception (December 24, 1997). To date, these losses and cash flow
deficiencies have been financed principally through the sale of
common stock ($447,200) and short term debt ($1,416,682) which is
related party debt. Additional capital and/or borrowings will be
necessary in order for the Company to continue in existence until
attaining and sustaining profitable operations. Management has
continued to develop a strategic plan to develop a management team,
maintain reporting compliance and establish long term relationships
with other major organizations to develop and distribute the product
Malarax. Management anticipates generating revenue through the sales
of Malarax during the next fiscal year. The major shareholder's of
the organization have committed to fund the operations of the
organization during the next fiscal year until the organization can
generate sufficient cash flow from operations to meet current
operating expenses and overhead.
7. Commitments, contingencies and litigation
Office rent agreement:
On December 27, 1997, the company entered into an office rent
agreement with 9033-0176 Quebec Inc. for office space. This agreement
also includes the full usage of all office equipment and
receptionist. This agreement is for a term of 5 year and the annual
rental amount is $79,325.
Auto Reimbursement
The company has agreed to reimburse Claude Villenueve, a shareholder,
each month an amount of $1,040 relating to auto expenses used in the
course of business.
8. Comprehensive income (loss)
The Company adopted Statement of Financial Accounting Standards (SFAS)
No. 130, "Reporting Comprehensive Income". SFAS 130 establishes
standards for the reporting and display of comprehensive income (loss)
and its components in the financial statements. The adoption of this
statement did not result in a change in the Company's disclosure.
9. Related Parties
As discussed in Note 4, the company has a promissory note with Claude
Villenueve, a shareholder, which is unsecured and bearing interest in
the amount of 8% annum. The amount at November 30, 1999 including
interest is $1,043,464 and has no maturity date.
As discussed in Note 6, the company has an agreement to reimburse
Claude Villenueve, a shareholder , monthly for auto expenditures a
standard amount of $1,040.
On January 9, 1998, the company entered into an agreement with
L'Espoir Du Millenaire Inc. whereby L'Espoir Du Millenaire Inc. has
marketing and distributor rights for the product Malarax. The
agreement is for 5 years and requires L'Espoir Du Millenaire Inc. to
make annual payments of $30,000 to Millenia Hope Inc. for the rights.
The agreement also allows for renewal of the agreement for an
additional 5 years provided that certain sales quotas have been met.
L'Espoir Du Millenaire Inc. is owned Mr. Claude Villenueve, a
shareholder in Millenia Hope Inc.
<PAGE>
MILLENIA HOPE INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
NOTES TO THE FINANCIAL STATEMENTS
YEARS ENDED NOVEMBER 30, 1999 AND 1998
10. Income Taxes
The Company did not provide any current or deferred United States
federal, state or foreign income tax provision or benefit for the
period presented because it has experienced operating losses since
inception. The Company has provided a full valuation allowance on the
deferred tax asset, consisting primarily of net operating loss
carryforwards, because of uncertainty regarding its realizability.
11. Shareholders' Equity
In December 1997, the company issued 4,000,000 shares of common stock
at a price of $0.00505 pursuant to an private placement offering exempt
from registration requirements under section 4(2) of the Securities Act
of 1933, as amended, and Rule 504 of Regulation D.
In February 1998, the company issued in accordance with it private
placement offering exempt from registration requirements under section
4(2) of the Securities Act of 1933, as amended, and Rule 504 of
Regulation D sold 6,100,000 units (each unit consisting of one (1 share
of common stock and (1) warrant) at a price of $0.07 per unit. Each
warrant entitles the registered holder thereof to purchase at any time
from the date of the offering until the close of business February 11,
2001, one share of common stock at a price of $0.09.
In March 1999, the Company issued 1,111,220 shares of common stock in
settlement of marketing agreements established with organizations for
their services which included the marketing of the Company and its
product Malarex globally. The total marketing cost was $1,514,215. The
company's share value on that date was trading on the OTC Bulletin
Board at $1.3627. The transaction was at arm's length with third
parties.
12. Warrants and Options
In 1998, the Company, in accordance with it private placement
memorandum to sell 6,100,000 units (each unit consisting of one (1)
share of common stock and one (1) warrant), sold 6,100,000 shares of
common stock. Each warrant entitles the registered holder thereof to
purchase at any time from the date for a period of three (3) years, one
share of common stock at a price of $0.09. As of November 30, 1999,
6,100,000 warrants were outstanding.
On January 29, 1999 the company granted 210,000 options to its
President, Leonard Stella. The options vest 70,000 per year over a
three year period. The options are exercisable at $1.50 per share and
expire on December 31, 2003. The total dollar value of the options at
the date of grant was $315,000. The fair market value of the company's
stock which was tradable on the OTC Bulleting Board was $1.50.
On January 29, 1999 the company granted 150,000 options to its Chief
Executive Officer, Dominique Morisot. The options vest 50,000 per year
over a three year period. The options are exercisable at $1.50 per
share and expire on December 31, 2003. The total dollar value of the
options at the date of grant was $225,000. The fair market value of the
company's stock which was tradable on the OTC Bulleting Board was
$1.50.
On January 29, 1999 the company granted 50,000 options to its Vice
President Human Resource, Ronald Lapenna. The options vest after one
year. The options are exercisable at $1.50 per share and expire on
December 31, 2003. The total dollar value of the options at the date of
grant was $75,000. The fair market value of the company's stock which
was tradable on the OTC Bulleting Board was $1.50.
<PAGE>
MILLENIA HOPE INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
NOTES TO THE FINANCIAL STATEMENTS
YEARS ENDED NOVEMBER 30, 1999 AND 1998
Warrants and Options (continued)
On January 29, 1999 the company granted 50,000 options to its Vice
President Finance, George Haligua. The options vest after one year. The
options are exercisable at $1.50 per share and expire on December 31,
2003. The total dollar value of the options at the date of grant was
$75,000. The fair market value of the company's stock which was
tradable on the OTC Bulleting Board was $1.50.
On August 30, 1999, the Company granted 100,000 options to its chairman
of the Board, Dr. Alain Soucy. The options vest after one year. The
options are exercisable at $0.30 per share and expire on December 31,
2003. The total dollar value of the options at the date of grant was
$30,000. The fair market value of the company's stock which was
tradable on the OTC Bulleting Board was $.30.
In October 1995, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standards ("SFAS") No. 123,
"Accounting for Stock-Based Compensation". The Company has determined
that it will continue to account for employee stock-based compensation
under Accounting Principles Board No. 25 and elect the disclosure-only
alternative under SFAS No. 123. The fair value of a share of nonvested
stock is measured at the market price of a share on the grant date. The
proforma effect to net income and earnings per share is reflected as
follows:
<TABLE>
<S> <C> <C>
Year ended Year ended
FAS 123 "Accounting for stock based compensation Nov. 30, 1999 Nov. 30, 1998
------------- -------------
Paragraph 47 (a)
1. Beginning of year - outstanding
i. number of options 0 0
ii. weighted average exercise price 0 0
2. End of year - outstanding
i. number of options 560,000 0
ii. weighted average exercise price 1.29 0
3. End of year - exercisable
i. number of options 0 0
ii. weighted average exercise price 0 0
4. During the year - Granted
i. number of options 560,000 0
ii. weighted average exercise price 1.29 0
5. During the year - Exercised
i. number of options 0 0
ii. weighted average exercise price 0 0
6. During the year - Forfeited
i. number of options 0 0
ii. weighted average exercise price 0 0
7. During the year - Expired
i. number of options 0 0
ii. weighted average exercise price 0 0
Paragraph 47 (b) Weighted-average grant-date fair
value of options granted during the year:
1. Equals market price 1.29 0
2. Less than market price 1.41 0
Paragraph 47(C)Equity instruments other than options none none
</TABLE>
<PAGE>
MILLENIA HOPE INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
NOTES TO THE FINANCIAL STATEMENTS
YEARS ENDED NOVEMBER 30, 1999 AND 1998
Warrants and Options (continued)
<TABLE>
<S> <C> <C>
Paragraph 47(d) Description of the method and significant
assumptions used during the year to estimate the fair value of options:
1. Weighted average risk-free interest rate 6.10% 0
2. Weighted average expected life 56.74 months 0
3. Weighted average expected volatility 128.00% 0
4. Weighted average expected dividends 0.00 0
Paragraph 47(e) Total compensation cost recognized in income for 0 0
stock-based employee compensation awards.
Paragraph 47(f) The terms of significant modifications of none none
outstanding awards. Paragraph 48 - Options outstanding at the date of
the latest statement of financial position presented:
1. (a) Range of exercise prices $0.30-$1.50 0
(b) Weighted-average exercise price 1.29 0
2. Weighted-average remaining contractual life (in months) 56.74 0
Inception
Dec. 24, 1997
Year ended Year ended Through
Nov. 30, 1999 Nov. 30, 1998 Nov. 30, 1999
------------------ ----------------- -------------
Net Income after proforma effect (1,773,702) (746,050) (2,519,752)
Earnings per share after proforma effect $ (0.1605) $ (0.0739) $ (0.2348)
</TABLE>
13. Earnings (Loss) per common share
Basic earnings (loss) per share is computed using the weighted-average
number of common shares outstanding during the period. Options and
warrants are not considered since considering such items would have an
antidilutive effect.
<PAGE>
Index to Exhibits
3.1 Certificate of Incorporation
3.2 By-Laws
4.1 Form of Stock Certificate*
10.1 Purchase Agreement for Voacamine
10.2 Purchase Agreement for Research Data
10.3 Purchase Agreement for Strychonos
10.4 Licensing Agreement with L'ESPOIR Du Millenaire Inc.
10.5 Service Agreement wih Richgold Corporations SA**
10.6 Lease Agreement
16 Letter From Terminated Auditor**
27 Financial Data Schedule
99 Auditors Opinion 1998**
----------------------
* To be filed by Amendment
**Filed herewith
23
<PAGE>
SIGNATURES
In accordance with Section 12 of the Securities Exchange Act of 1934, the
Registrant caused this registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized.
MILLENIA HOPE INC.
Date: September 29, 2000 /s/Alain Soucy
-----------------------
Alain Soucy, Chairman
Date: September 29, 2000 /s/Leonard Stella
--------------------------------------
Leonard Stella, President and Director
Date: September 29, 2000 /s/Dominique Morisot
-----------------------------------
Dominique Morisot, CEO and Director
Date: September 29, 2000 /s/George Haligua
----------------------------------------------------
George Haligua, VP Finance and Director (Principal
Financial Officer)
Date: September 29, 2000 /s/Ronald Lapenna
----------------------------------------------------
Ronald Lapenna, VP Personnel and Director
24
